Compare Harley-Davidson Inc (HOG) vs Summit Therapeutics Inc (SMMT) Price & Performance

Harley-Davidson (HOG) trades at $26.83, down 0.45% with a bullish technical signal and mixed earnings performance. The stock shows attractive valuation metrics with P/E of 14.86 and P/S of 0.72, while revenue has declined from $5.8B in 2022 to $4.5B in 2025. Recent Q2 2026 earnings beat expectations with $0.75 EPS versus $0.645 expected, though Q1 and Q4 2025 results missed targets. The company maintains a dividend payout with recent $0.1875 declaration.

Outlook remains cautious as revenue declines and margin compression continue, though valuation appears reasonable. Key risks include tariff exposure, competitive pressures, and ongoing revenue contraction. Analyst consensus targets $28.50 with mixed sentiment (27.78% Buy, 61.11% Hold). The stock offers value characteristics but faces fundamental headwinds requiring careful monitoring of turnaround execution.

Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.

The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.